Kunitz type protease inhibitor EgKI-1 from the canine tapeworm Echinococcus granulosus as a promising therapeutic against breast cancer

Ranasinghe, Shiwanthi L., Boyle, Glen M., Fischer, Katja, Potriquet, Jeremy, Mulvenna, Jason P., and McManus, Donald P. (2018) Kunitz type protease inhibitor EgKI-1 from the canine tapeworm Echinococcus granulosus as a promising therapeutic against breast cancer. PLoS ONE, 13 (8). e0200433.

[img]
Preview
PDF (Published Version) - Published Version
Available under License Creative Commons Attribution.

Download (12MB) | Preview
View at Publisher Website: https://doi.org/10.1371/journal.pone.020...
 
24


Abstract

EgKI-1, a member of the Kunitz type protease inhibitor family, is highly expressed by the oncosphere of the canine tapeworm Echinococcus granulosus, the stage that is infectious to humans and ungulates, giving rise to a hydatid cyst localized to the liver and other organs. Larval protoscoleces, which develop within the hydatid cyst, have been shown to possess anti-cancer properties, although the precise molecules involved have not been identified. We show that recombinant EgKI-1 inhibits the growth and migration of a range of human cancers including breast, melanoma and cervical cancer cell lines in a dose-dependent manner in vitro without affecting normal cell growth. Furthermore, EgKI-1 treatment arrested the cancer cell growth by disrupting the cell cycle and induced apoptosis of cancer cells in vitro. An in vivo model of triple negative breast cancer (MDA-MB-231) in BALB/c nude mice showed significant tumor growth reduction in EgKI-1-treated mice compared with controls. These findings indicate that EgKI-1 shows promise for future development as an anti-cancer therapeutic.

Item ID: 55623
Item Type: Article (Research - C1)
ISSN: 1932-6203
Copyright Information: © 2018 Ranasinghe et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funders: National Health and Medical Research Council (NHMRC)
Projects and Grants: NHMRC program APP1037304
Date Deposited: 19 Sep 2018 09:35
FoR Codes: 11 MEDICAL AND HEALTH SCIENCES > 1112 Oncology and Carcinogenesis > 111201 Cancer Cell Biology @ 50%
11 MEDICAL AND HEALTH SCIENCES > 1112 Oncology and Carcinogenesis > 111204 Cancer Therapy (excl Chemotherapy and Radiation Therapy) @ 50%
Downloads: Total: 24
Last 12 Months: 20
More Statistics

Actions (Repository Staff Only)

Item Control Page Item Control Page